Morimatsu International Holdings Company Limited (HK:2155) has released an update.
Morimatsu International Holdings has disclosed the identities and capital contributions of key participants in its Share Incentive Scheme for its subsidiary, Morimatsu Pharmaceutical. The scheme involves prominent directors and employees with a total investment of RMB12,868,710, aiming to bolster the company’s financial position and strategic growth in the pharmaceutical industry. The valuation process utilized a market approach, comparing price-to-book ratios with similar A-share listed companies to ensure a comprehensive reflection of Morimatsu’s market value.
For further insights into HK:2155 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
